

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Sinco Pharmaceuticals Holdings Limited**

**兴科蓉医药控股有限公司**

*(Incorporated under the laws of the Cayman Islands with limited liability)*

**(Stock Code: 6833)**

**SUPPLEMENTAL ANNOUNCEMENT ON  
DISCLOSEABLE TRANSACTION  
IN RELATION TO  
THE TECHNOLOGICAL DEVELOPMENT PROJECT**

Reference is made to the announcement of Sinco Pharmaceuticals Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 9 September 2021 in relation to the Technological Development Project (the “**Announcement**”). Unless otherwise defined herein, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

The Company would like to provide supplemental information on the identities of the ultimate beneficial owners of Beijing Nuokangda. As at the date of the Announcement and up to the date hereof, to the best knowledge, information and belief of the Board, (i) Ms. Tao Xiumei and Mr. Chen Peng are the largest ultimate beneficial owners of Beijing Nuokangda, holding approximately 27.4% and approximately 13.5% equity interest, directly and indirectly, in Beijing Nuokangda, respectively, and the remaining equity interest in Beijing Nuokangda is ultimately owned by a number of shareholders; and (ii) save for the Master Cooperation Agreement and the Technological Development Agreements in relation to the Technological Development Project, the Group has not entered into any significant relationship with Beijing Nuokangda or its connected persons.

The supplementary information provided herein does not affect other information contained in the Announcement and should be read in conjunction with the Announcement.

By order of the Board  
**Sinco Pharmaceuticals Holdings Limited**  
**Huang Xiangbin**  
*Chairman and Executive Director*

Sichuan, the PRC, 21 October 2021

*As at the date of this announcement, the executive Director is Mr. Huang Xiangbin; and the independent non-executive Directors are Mr. Lau Ying Kit, Mr. Wang Qing, Mr. Liu Wenfang and Mr. Bai Zhizhong.*